Gapping up
Other news:
- SNGX +11.7% (announces USPTO granted the patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis")
- DPW +10.6% (subsidiary CooliSys enters agreement to acquire Enertec Systems, a subsidiary of Micronet Enertec Technologies),
- WATT +10.3% (Continued momentum from last week; Positive mention in WSJ; CEO sells 75K shares),
- PLX +10% (announces interim data from the first 14 patients that completed, to date, the Company's phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis),
- EROS +8.1% (Continued momentum from last week's announcement that it is available on AMZN),
- RENN +5.2% (Continued momentum from last week's acquisition announcement),
- JMEI +4.4% (Continued momentum from Friday's earnings news),
- BGNE +2.3% (initiates global phase 3 Trial of Anti-PD-1 antibody tislelizumab in patients with hepatocellular carcinoma).
Analyst comments:
- BCRX +3.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts),
- TITN +3.7% (upgraded to Mkt Perform at William Blair),
- ABT +2.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley),
- INCY +2.4% (upgraded to Outperform from Sector Perform at RBC Capital Mkts),
- BT +2.2% (upgraded to Buy from Neutral at BofA/Merrill),
- STO +2.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts),
- JWN +1.8% (upgraded to Neutral from Underweight at JP Morgan),
- NFLX +1.7% (upgraded to Outperform from Neutral at Macquarie),
- SYK +1.4% (upgraded to Overweight from Neutral at JP Morgan),
- TER +1.1% (upgraded to Outperform from In-line at Evercore ISI),
- MDT +1.1% (upgraded to Buy from Neutral at BofA/Merrill ),
- LB +1.1% (upgraded to Outperform at Robert W. Baird; tgt raised to $70).